We have collected information about Coronary Drug Delivery for you. Follow the links to find out details on Coronary Drug Delivery.
https://citoday.com/articles/2017-jan-feb/current-use-of-coronary-drug-coated-balloons
Around the time that the first coronary DES (Cypher, Cordis Corporation) was introduced in Europe in 2002, Ulrich Speck, PhD, and Bruno Scheller, MD, set out to develop a novel method for local antiproliferative drug delivery that was not stent-based in order to …
https://www.accessdata.fda.gov/cdrh_docs/pdf16/P160043C.pdf
The Medtronic Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System (Resolute Onyx™ system) consists of a balloon-expandable, intracoronary, drug-eluting stent (DES) premounted on a Rapid Exchange (RX) or an Over-the-Wire (OTW) stent delivery system. The Resolute Onyx™ stent is manufactured from a composite material of cobalt alloy and
https://www.sciencedirect.com/science/article/pii/S0735109720300978
Percutaneous coronary intervention with a drug-eluting stent is the most common mode of revascularization for coronary artery disease. However, restenosis rates remain high. Non-stent-based local drug delivery by a drug-coated balloon (DCB) has been investigated, as it leaves no metallic mesh.Author: Charan Yerasi, Brian C. Case, Brian J. Forrestal, Rebecca Torguson, William S. Weintraub, Hector M. ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC351659/
Intravenous delivery increased circumflex flow an average of 34%, increased carotid flow 41%, and decreased systemic arterial pressure 13%. The technique has immediate research and potential clinical application as a means of preferentially delivering diagnostic or therapeutic agents, such as thrombolytics, to the coronary circulation.Author: James H. Anderson, Cesare Gianturco, Sidney Wallace, Gerald D. Dodd
https://www.ahajournals.org/doi/10.1161/01.CIR.0000050367.65079.71
Fixed drug release kinetics and vessel wall partitioning may limit the effectiveness of present drug-eluting stents. 1–3 A new type of metallic stent has been engineered specifically as a next-generation coronary drug delivery system that allows precise and programmable control over spatial and temporal release kinetics and substantially enhances drug-loading capacity.Author: Ariel Finkelstein, Dougal McClean, Saibal Kar, Kaname Takizawa, Kiron Varghese, Namjin Baek, Kinam P...
https://www.ncbi.nlm.nih.gov/pubmed/23158532
Dec 18, 2012 · 1. J Am Coll Cardiol. 2012 Dec 18;60(24):2550-7. doi: 10.1016/j.jacc.2012.08.1008. Epub 2012 Nov 14. A new drug delivery system for intravenous coronary thrombolysis with thrombus targeting and stealth activity recoverable by ultrasound.Author: Hiroyuki Kawata, Yoshiko Uesugi, Tsunenari Soeda, Yasuhiro Takemoto, Ji-Hee Sung, Kiyotaka Umaki, Ke...
http://www.onlinejacc.org/content/75/9/1061
Mar 10, 2020 · Percutaneous coronary intervention with a drug-eluting stent is the most common mode of revascularization for coronary artery disease. However, restenosis rates remain high. Non-stent-based local drug delivery by a drug-coated balloon (DCB) has been investigated, as it leaves no metallic mesh. A DCB consists of a semicompliant balloon coated with antiproliferative agents encapsulated in a ...Author: Charan Yerasi, Brian C. Case, Brian J. Forrestal, Rebecca Torguson, William S. Weintraub, Hector M. ...
https://www.sciencedirect.com/science/article/pii/S0019483217301050
The review is structured into the following subsections: historical context, nanomedicine based drug delivery, global mortality burden of coronary artery disease (CAD), nanomedicine therapeutic options for CAD (non-invasive and invasive therapy), nanomedicine and imaging, challenges facing routine nanomedicine application in treating CAD and ...Author: Paurush Ambesh, Umberto Campia, Chukwudi Obiagwu, Rashika Bansal, Vijay Shetty, Gerald Hollander, Ja...
https://www.drugdeliverybusiness.com/fda-approves-abbotts-latest-drug-eluting-stent/
May 23, 2018 · Abbott (NYSE:ABT) said today that it won FDA approval for its Xience Sierra everolimus-eluting coronary stent.. The company’s device features a thin profile, improved flexibility and longer lengths than previous stents. The device and delivery system were designed to help clinicians tackle complex cases, like those involving multiple or totally blocked vessels, according to Abbott.
Searching for Coronary Drug Delivery?
You can just click the links above. The data is collected for you.
